General Information of Drug (ID: DMLXFHD)

Drug Name
BS-194 Drug Info
Synonyms CDK inhibitors (cancer), Imperial College London/Emory University
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
PubChem CID
25125014
CAS Number
CAS 1092443-55-4
TTD Drug ID
DMLXFHD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [3]
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [4]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [5]
PF-06873600 DMRZHV6 Breast cancer 2C60-2C65 Phase 1 [5]
PMID26161698-Compound-44 DM8UPO3 N. A. N. A. Patented [6]
Purine derivative 4 DMYD5SQ N. A. N. A. Patented [6]
Indole-based analog 12 DM1CNRH N. A. N. A. Patented [6]
PMID26161698-Compound-10 DMXVCHZ N. A. N. A. Patented [6]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase (CDK) TTMBO1Z NOUNIPROTAC Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8176).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8176).
3 Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24.
4 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.